Renowned Speakers

David H. Van Thiel

University Medical Center, USA, USA

Dimitar tonev

Senior medical director, UK, UK

Antonio Iannetti

University â€œLa Sapienzaâ€ Roma, Italy, Italy

CÃ©line Tiffon

University Hospital Bern, Switzerland, Switzerland

Fong-Fong Chu

Henan University of Science and Technology, USA, USA

Bashar Attar

Rush University Medical Center, USA, USA

Jay-lin Jane

Iowa State University USA, USA

Pierluigi Fracasso

Secretary of the European Society of Primary Care Gastroenterology, Italy, Italy

Recommended Global Gastroenterology Webinars & Conferences

Europe & UK

Earth science-2025, France Gastroenterology Conference 2025, France Liver Diseases 2025, UK

Asia Pacific & Middle East

WORLD GASTROENTEROLOGY 2025, UAE

Canada

Gastroenterology 2025, Scotland

HEPATITIS 2025

Welcome Message

We are honoured and thrilled to welcome you all to the “8th International Congress on Viral Hepatitis” scheduled on March 10-11, 2025 at Paris, France, with the theme “Advancements in Hepatitis Diagnostics and Screening”

It is an opportunity to network with Doctors, professors, scientists, Specialists, educationalists, renowned speakers, researchers, and students from all over the world who have interest in sharing their research experience and practical knowledge within the arena of Gastroenterology and Liver diseases to a most exciting and memorable scientific meeting to announce and witness the recent scientific and technological advancements in Gastroenterology and Hepatology.

About Conference

The 8th International Congress on Viral Hepatitis invites all the participants across the globe to attend and share their insights and convey recent complications and advancements and in the field of Gastroenterology follows the theme “Advancements in Hepatitis Diagnostics and Screening” which will be held on March 10-11, 2025 at Paris, France.

HEPATITIS 2025 offers an opportunity to meet and make new contacts in relevant fields of Gastroenterology, Hepatology, Diabetes, Obesity, Nutrition and Health Care. The new form of innovations and researches get encouraged and providing an opportunity to the persons who are attending to the conference. It allows delegates to have issues addressed on Gastroenterology and Hepatology by recognized global experts who are up to date with the latest developments in the respective field and provide information on new innovations and technologies.

HEPATITIS 2025 unites the worldwide pioneers who are involved in the arena of Gastroenterology and Hepatology to explore their research work in the conference. It provides a great chance to collaborate with global business delegates and researchers and it is all set to be adorned by world renowned speakers.

Tracks

Track-1: Hepatitis Types

Dive into the various types of Hepatitis (A, B, C, D, E), examining their modes of transmission, clinical features, and differences in management. This session will provide a comprehensive overview of each type's unique challenges.

Conferences: International Liver Congress (ILC) 2025 | Global Hepatitis Summit 2025 | World Hepatitis Day Conference 2025 | Liver Diseases and Hepatology Summit 2025 | Annual Viral Hepatitis Congress 2025 | Global Public Health and Hepatitis Conference 2025

Track-2: Hepatitis Vaccines

Review the latest advancements in vaccine development for Hepatitis, including new candidates and strategies to increase global vaccine coverage. The session will also address challenges in vaccine distribution and uptake.

Track-3: HBV Management

Focus on the latest guidelines and treatment protocols for managing Hepatitis B Virus (HBV) infection, including antiviral therapies and monitoring strategies. Discussions will cover both chronic and acute cases of HBV.

Track-4: HCV Treatment

Explore the evolving landscape of Hepatitis C Virus (HCV) treatment, including the latest direct-acting antivirals (DAAs), and strategies to achieve sustained virologic response (SVR). Emerging therapies and access to care will also be discussed.

Track-5: Immune Response

This session will delve into the immune system’s response to Hepatitis infections, discussing how immunity is developed, the role of immune evasion by viruses, and the implications for vaccine development and therapeutic interventions.

Track-6: Special Populations

Address the unique challenges in diagnosing and treating Hepatitis in special populations, including pregnant women, children, the elderly, and immunocompromised patients. The session will explore tailored approaches to care in these groups.

Track-7: Hepatitis Co-Infections

Examine the clinical complexities and treatment strategies for patients co-infected with Hepatitis and other infections, such as HIV. The session will highlight the challenges of managing co-infections and optimizing therapeutic outcomes.

Track-8: Liver Fibrosis & Cirrhosis

This session focuses on the progression of liver fibrosis and cirrhosis in Hepatitis patients, discussing the latest diagnostic tools, treatment options, and strategies to prevent or reverse liver damage.

Track-9: Diagnostic Technologies

Highlight the latest advancements in diagnostic technologies for Hepatitis, including early detection methods, non-invasive tests, and the role of biomarkers in monitoring disease progression.

Track-10: Hepatitis & Liver Cancer

Explore the link between chronic Hepatitis infections and the development of liver cancer, particularly hepatocellular carcinoma. The session will cover screening protocols, early detection, and preventive measures.

Track-11: Public Health Policies

Discuss the role of public health policies in controlling Hepatitis, including national and global strategies for prevention, vaccination, and treatment. The session will highlight successful policy interventions and areas needing improvement.

Track-12: Prevention Programs

Review various prevention programs aimed at reducing the transmission of Hepatitis, including harm reduction initiatives, educational campaigns, and community outreach efforts. The session will focus on effective strategies for high-risk populations.

Track-13: Antiviral Resistance

This session will address the growing concern of antiviral resistance in Hepatitis treatment, exploring the mechanisms of resistance, its impact on treatment efficacy, and strategies to manage and prevent resistance.

Track-14: Nutrition in Hepatitis

Discuss the role of diet and nutrition in the management of Hepatitis, including dietary recommendations, the impact of malnutrition on liver disease progression, and the role of nutritional supplements in patient care.

Track-15: Psychosocial Factors

Explore the psychosocial aspects of living with Hepatitis, including the mental health challenges, stigma, and social impacts faced by patients. The session will also discuss support systems and interventions to improve quality of life.

Track-16: Substance Abuse

Examine the link between substance abuse, particularly intravenous drug use, and the transmission of Hepatitis. The session will focus on harm reduction strategies and the importance of integrating substance abuse treatment with Hepatitis care.

Track-17: Research Innovations

Highlight the latest research innovations in the field of Hepatitis, including new therapeutic targets, vaccine development, and novel approaches to treatment and prevention. The session will also discuss future directions for research.

Track-18: Global Health Initiatives

Discuss international collaborations and initiatives aimed at combating Hepatitis on a global scale. The session will highlight successful programs and the ongoing challenges in achieving global Hepatitis elimination by 2030.

Track-19: Patient-Centered Care

Focus on the importance of patient-centered approaches in Hepatitis care, including strategies to improve patient engagement, adherence to treatment, and overall quality of care. The session will also cover personalized treatment plans and patient education.

Track-20: Global Hepatitis Burden

This session explores the worldwide impact of Hepatitis, highlighting the epidemiological trends, regions most affected, and the societal and economic burden of the disease. Discussions will include current efforts to reduce incidence and mortality rates.

Participation/Presentation Options

Oral presentation: Oral Presentations may include the topics from researches, theoretical, professional or private practices in a concise manner. Individuals with personal experience are also welcome to present personal experiences or narratives which help others in everyday life. Speakers with a 30-minute slot should plan to speak for 20-25 minutes, and Keynote speakers should plan to speak for 40-45 minutes, with the remaining time to be used for questions and discussion by the Session Chair.

Workshop: For workshop presenters also, the topic of the talk will be the same as an Oral presentation with more specialized techniques and detailed demonstration. The generalized time duration for a workshop presentation is about 45-50 minutes. Interested participants can join with their respective team and present the workshop with their research coordinators with special group waivers on registration.

Poster presentation: Student Poster Competition will be organized at the Hepatitis 2025 conference is to encourage students and recent graduates to present their original research. Presenters will be given about 5-7 minutes to present the poster including questions and answers. Judges may ask questions during the evaluation of the presentation. This is an opportunity for young scientists to learn about the recent findings of their peers to increase their capacity as multidisciplinary researchers. Poster displays will be in hard copy format of 1x1 M long.

For more details regarding Poster Presentation and Judging Criteria view Poster Presentation Guidelines.

Webinar: The webinar presentation is designed for those interested attendees who cannot join in person due to schedule conflicts or other obligations. In this option, the presenter may record the presentation and their presentation will be presented in the Webinar presentation session.

E-Poster: e-Poster is also similar to the webinar presentation. In this session, their presentation will be published in the form of a poster in the conference website and the presenter abstract will be published in the conference souvenir and journal with DOI.

Exhibition: Hepatitis 2025 has the opportunity to exhibit the products and services from commercial and non-commercial organizations like Drug manufacturers, Clinical Trial Sites, Management Consultants, Chemists, Pharmacists, Business delegates and Equipment Manufacturers.

To know more about exhibitor booth details and benefits visit WHY TO EXHIBIT WITH US?

Send your queries to contact@globalconferencemeet.com

Advertisement: The conference program is a valuable resource that all attendees refer again and again as they navigate the conference. Advertising in the conference program is a great way to market and can help you secure long term business.

Send your proposal to contact@globalconferencemeet.com to know the available advertisement options and prices

Sponsor Liver Disease 2025

Premium Sponsorship package

Additional Sponsorship package

Mail the program manager at contact@globalconferencemeet.com or WhatsApp on (+44 7418315935) to know more about the sponsorship packages.

Market Analysis

HEPATITIS 2025 is the best platform for all recognized/ under- recognized scholastics in the field of Liver, Gastroenterology, Hepatology, Health specialists, analysts, educational scientists, Industry researchers, scientists to exchange about research and developments in grounds of Gastroenterology. The main focus of this meeting is to invigorate and globalize new thoughts and researches for treatment and to determine the current market for proceeding towards future of Gastro medicine, operational devices and diagnostics, with an accentuation on new technology that will be advantageous in the field of Gastroenterology and Hepatology.

The global gastrointestinal therapeutics market size was valued at USD 37.6 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 3.3% from 2023 to 2030. The increasing prevalence of gastrointestinal disorders such as IBS, Crohn’s disease, and ulcerative colitis and the rising demand for gastrointestinal (GI) drugs are the major factors driving the market growth. Moreover, the surge in R&D efforts by pharmaceutical companies to develop novel GI drugs and increasing product approvals are expected to enhance market growth during the forecast period.

According to the GI Alliance data from February 2021, it is estimated that around 20 million Americans suffer from chronic digestive diseases and over 62 million Americans are diagnosed with gastrointestinal diseases annually and the incidence of gastrointestinal disorders rises with age. Moreover, as per data published by the International Foundation for Gastrointestinal Disorders, Inc. (IFFGD), the prevalence of GERD is 18-28% in North America, 23% in South America and 9-26% in Europe. Thus, the high prevalence of gastrointestinal diseases is likely to drive market growth in the coming years.